Day: November 5, 2020

medicine

Editas Medicine (EDIT) Tops Q3 Earnings and Revenue Estimates

Editas Medicine (EDIT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of a loss of $0.66 per share. This compares to loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 118.18%. A quarter ago, it was expected that this genome editing company would post a loss of $0.80 per share when it actually produced a loss of $0.43, delivering a surprise of 46.25%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Editas, which belongs to the Zacks Medical – Biomedical and Genetics industry, posted revenues of $62.84 million for the quarter ended September 2020, surpassing the Zacks Consensus Estimate by 759.42%. This compares to year-ago revenues of $3.85 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings call.

Editas shares have added about 2.8% since the beginning of the year versus the S&P 500’s gain of 6.6%.

What’s Next for Editas?

While Editas has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Editas was mixed. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.89 on $6.57 million in revenues for the coming quarter and -$2.67 on $29.49 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical – Biomedical and Genetics is currently in the bottom 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform

Read More
medicine

Rochester author explores psychology, medicine, more

Paul John Scott’s book “Malcharist,” while imminently entertaining, is also thought-provoking and deeply disturbing. It invites the reader to consider the perils created when science succumbs to marketing while telling a tale about side effects, suicide, patients, doctors, journalists and medical ghostwriters.

Scott is an established journalist currently employed by Forum Communications. While he’s written for publications like The New York Times, Cosmopolitan and Men’s Health, his debut novel exhibits a knack for both clever dialogue and making dense ideas enjoyable.

What was the process like, bringing the book from concept to publication?

I used to spend a lot of time waiting for an editor to let me write articles on some of these subjects in “Malcharist.” They were kind of radioactive, is my impression. I also had been wanting really badly to break out of the journalism drudgery of needing to constantly learn something new in a hurry, polish it for weeks, and then drop it forever. I had been excited to write about small conversations people have with each other, all these funny thoughts a person has all day.

So one day back in about 2012, I must have become extraordinarily frustrated while waiting for an editor to email me back because I turned to my heroically understanding wife and said I think I want to just write a novel. I told her it would take no more than six weeks, and it ended up taking eight years.

I bought books on how to write novels. I had no idea how to write dialogue or point of view or plot or backstories. It was all exposition, people blabbing on and on. I threw out hundreds of pages. I stopped and started. I hired an editor. I renamed the book, the characters, changed the setting. I showed early drafts to friends, and, after one really brutal evaluation, I put it away for a year. I was too stubborn to move on.

What did a typical day of writing “Malcharist” look like for you?

No real typical day. I had an idea of a beginning and an end, and even bought a whiteboard and notecards to plot out the in-between, but I never used it that much. I wrote things on napkins and stole phrases I liked from people who say clever things and go back to jam them in the book. I would write a scene and polish it to death and eventually come to hate it. There was lots of procrastination on social media, until one day I quit Facebook just to free up time, and that really helped a lot.

The first 100 pages came easy, the second 100 pages were filled with doubt and despair, and then I found I had hundreds of pages more in me as the end approached. Sometimes I would work in the early evening just to salvage the day’s output, but I tried to never work past 10 because it was usually not as good in the morning as you thought

Read More
medicine

Editas Medicine Announces Third Quarter 2020 Results and Update

EDIT101 for LCA10 BRILLIANCE trial adult low-dose cohort completed

EDIT-301 for sickle cell disease on track for IND filing by end of 2020

EDIT-201 for solid tumors preclinical data to be presented at SITC and ASH

Cash, cash equivalents, and marketable securities of $541 million as of September 30, 2020

CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the third quarter of 2020.

“We were pleased to regain full operating control of our ocular programs per our new agreement with AbbVie, which provides us with important flexibility. We have finished dosing the first cohort with EDIT-101 in the landmark BRILLIANCE trial and enrollment remains active,” said Cynthia Collins, Chief Executive Officer of Editas Medicine.

Ms. Collins continued, “The advancements in our ocular portfolio are complemented by the strategic development of our engineered cell medicines. We are on track to file the IND for EDIT-301 for sickle cell disease in the fourth quarter and are eager to present additional data on this potentially best-in-class medicine and our large-scale manufacturing process at the upcoming American Society of Hematology Annual Meeting. Substantial progress has also been made in the development of EDIT-201, an allogeneic NK cell medicine to treat solid tumors. Preclinical data to be presented at ASH show enhanced tumor killing with EDIT-201 compared to unedited NK cells, and additional data on this program will be featured at the upcoming Society for Immunotherapy of Cancer’s Annual Meeting.”

Recent Achievements and Outlook

In Vivo CRISPR Medicines  

  • EDIT-101 for LCA10
    BRILLIANCE Phase1/2 adult low-dose cohort completed
    Editas Medicine (Company) has completed dosing of the first cohort of adult patients with visual light perception only administered the low dose of EDIT-101. Trial enrollment remains active but has experienced a slowdown due to the ongoing impact of the COVID-19 pandemic. 

  • Ocular Medicines
    Regained full control of ocular medicines
    Editas Medicine terminated its 2017 agreement with Allergan, now part of AbbVie, and entered a new agreement with AbbVie that returned development and commercialization rights for ocular medicines to Editas Medicine. As part of the new agreement, AbbVie has transferred supplier contracts, including with the contract research organization (CRO), as well as sponsorship of the investigational new drug application (IND) for the BRILLIANCE Phase 1/2 clinical trial to Editas Medicine. The Company plans to continue to advance ocular medicines, including EDIT-101 for Leber congenital amaurosis 10 (LCA10).

Ex Vivo CRISPR Cell Medicines  

  • EDIT-301 for Sickle Cell Disease and Beta-Thalassemia
    On track for IND filing by end of 2020
    Editas Medicine continues to prepare for a Phase 1/2 clinical trial evaluating EDIT-301 for the treatment of sickle cell disease. The Company has completed preclinical toxicology studies, identified a lead principal investigator, and engaged a CRO. Clinical trial materials are being manufactured by Editas Medicine. The Company remains on track to file an IND for the treatment of sickle cell disease by

Read More
medicine

IMA on integrated medicine proposal- The New Indian Express

By PTI

NEW DELHI: The Indian Medical Association (IMA) on Thursday said it is “highly perturbed” by the recent policy proposals for integration of all systems of medicine, calling it a “khichdi medical system” which could put millions of lives at risk.

In a statement, the organisation of doctors said it stands for purity of systems of modern medicine as well as Ayush and that this new system will provide “hybrid doctors” and the choice of the patient is effectively nullified.

“It is not in the interest of traditional systems either to lose their identity and further development. As such 96 per cent patients in IPD and 94 per cent of patients in OPD are being served by modern medicine,” it said.

“Currently, a patient has the choice of choosing either modern medicine or alternative system as per their desire. Unfortunately, the khichdi medical system that is being envisaged will provide only hybrid doctors and the choice of the patient is effectively nullified,” the statement said.

It claimed that NITI Aayog has formed four committees to integrate all systems of medicine.

These committees are in the area of medical education, clinical practice, public health, medical research and administration.

The theoretical basis of policy seems to emanate from the new National Education Policy.

Warning that the radical changes that are being institutionalised will have series impact on the health of people and can put millions of lives at risk, the IMA said it is “highly perturbed” by the move.

“The most important policy shift is from multiple dedicated medical streams to a system of integrative medicine. In simple words, what is being envisaged is to mix systems of medicine together in curriculum, practice and research. This retrograde step of unscientific mixing of systems of medicine will produce hybrid doctors who are nowhere,” the statement said.

“IMA has an IMA-Medical Student Network in 287 medical colleges of the country. The medical students of this country are equally concerned about their career and future. IMA MSN has joined hands with IMA in this campaign against quackery, mixopathy and crosspathy. IMA also demands that the PG NEET examination postponed without any notice should be held on schedule,” it said.

Source Article

Read More
medicine

Igentify, Genosity cooperate to bring precision medicine to all markets

Israeli digital health company Igentify will cooperate with US-based biotech firm Genosity to deliver the next step in precision medicine to all markets. Precision medicine is a new trend in the healthcare industry, Igentify director of partnerships Yael Furman told The Jerusalem Post.  

“Imagine a person suffering from a headache,” she said, “that person would take an aspirin. The drug is produced for all people who suffer from a headache. Yet in some cases, such as cancer, it’s extremely useful to know the genetic profile of the patient as that would make the treatment a lot more effective.” 

This still means mass-produced drugs for the most common genetic types in a given population, but perhaps drugs will eventually be made for the unique individual who needs them.  

The trend is coupled with other leaps and bounds medicine is going through thanks to big data and the digital age. For example, a woman who has a genetic likelihood to suffer from breast cancer could get digital “pushes” in the form of texts and emails that will remind her to get tested. Better and more frequent testing saves lives.  

“People see our animated videos and forget the mountain of work that goes into genetic research,” Igentify founder and CEO Dr. Doron Behar explains.  

“The videos are important because we want people to understand what the genetic test is, what will happen to their data, and to give their informed consent. Yet that is just the last step – what we do much more,” he said.

“There are only 7,000 genetic counselors in the world today,” Behar said. “This is a huge bottle neck that prevents people from having access to, and benefiting from, their own genetic data. Machine learning can take some of that burden off and deliver the service to more [people]. ”   

IGENTIFY HELPS medical service providers to set up the complex systems needed to decipher such data – from cheek swabs to lab robots to machine learning that is able to scan most possibilities of human genetic material creating a new life.   

“We use cheek swabs because they’re easier to do than blood samples and give us cells from the human cheek,” he explains, “it’s not the spit we’re after, it’s cells. Each cell has your entire genome in it.”  

If a man and a woman are thinking about having a baby together and if they have access to a genetic testing service, it could predict what is the likelihood of the yet-unborn child having a genetic disease based on the genetic analysis of both parents.  

A woman could use a simple cheek swab to learn if she is at risk of suffering from breast cancer. The information is presented in a friendly and easy to understand animated video that has a lot of planning behind it.   

“We’re able to offer this service not just in other languages but also with different avatars,” Behar pointed

Read More
medicine

December 24th Options Now Available For Editas Medicine

Investors in Editas Medicine Inc (Symbol: EDIT) saw new options become available today, for the December 24th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new December 24th contracts and identified one put and one call contract of particular interest.

The put contract at the $32.00 strike price has a current bid of $1.60. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $32.00, but will also collect the premium, putting the cost basis of the shares at $30.40 (before broker commissions). To an investor already interested in purchasing shares of EDIT, that could represent an attractive alternative to paying $32.20/share today.

Because the $32.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 100%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 5.00% return on the cash commitment, or 37.24% annualized — at Stock Options Channel we call this the YieldBoost.

Below is a chart showing the trailing twelve month trading history for Editas Medicine Inc, and highlighting in green where the $32.00 strike is located relative to that history:

Loading+chart+—+2020+TickerTech.com

Turning to the calls side of the option chain, the call contract at the $32.50 strike price has a current bid of $1.00. If an investor was to purchase shares of EDIT stock at the current price level of $32.20/share, and then sell-to-open that call contract as a “covered call,” they are committing to sell the stock at $32.50. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 4.04% if the stock gets called away at the December 24th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if EDIT shares really soar, which is why looking at the trailing twelve month trading history for Editas Medicine Inc, as well as studying the business fundamentals becomes important. Below is a chart showing EDIT’s trailing twelve month trading history, with the $32.50 strike highlighted in red:

Loading+chart+—+2020+TickerTech.com

Considering the fact that the $32.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website

Read More
medicine

IMA on integrated medicine proposal

New Delhi, Nov 5 (PTI) The Indian Medical Association (IMA) on Thursday said it is ‘highly perturbed’ by the recent policy proposals for integration of all systems of medicine, calling it a ‘khichdi medical system’ which could put millions of lives at risk.

In a statement, the organisation of doctors said it stands for purity of systems of modern medicine as well as Ayush and that this new system will provide ‘hybrid doctors’ and the choice of the patient is effectively nullified.

‘It is not in the interest of traditional systems either to lose their identity and further development. As such 96 per cent patients in IPD and 94 per cent of patients in OPD are being served by modern medicine,’ it said.

‘Currently, a patient has the choice of choosing either modern medicine or alternative system as per their desire. Unfortunately, the khichdi medical system that is being envisaged will provide only hybrid doctors and the choice of the patient is effectively nullified,’ the statement said.

It claimed that NITI Aayog has formed four committees to integrate all systems of medicine. These committees are in the area of medical education, clinical practice, public health, medical research and administration. The theoretical basis of policy seems to emanate from the new National Education Policy.

Warning that the radical changes that are being institutionalised will have series impact on the health of people and can put millions of lives at risk, the IMA said it is ‘highly perturbed’ by the move.

‘The most important policy shift is from multiple dedicated medical streams to a system of integrative medicine. In simple words, what is being envisaged is to mix systems of medicine together in curriculum, practice and research. This retrograde step of unscientific mixing of systems of medicine will produce hybrid doctors who are nowhere,’ the statement said.

‘IMA has an IMA-Medical Student Network in 287 medical colleges of the country. The medical students of this country are equally concerned about their career and future. IMA MSN has joined hands with IMA in this campaign against quackery, mixopathy and crosspathy. IMA also demands that the PG NEET examination postponed without any notice should be held on schedule,’ it said. PTI UZM SMN SMN

Source Article

Read More
medicine

Corporate Matching $200K Challenge Through December 2020 at ACMG Foundation for Genetic and Genomic Medicine

BETHESDA, Md., Nov. 5, 2020 /PRNewswire/ — The ACMG Foundation for Genetic and Genomic Medicine (ACMG Foundation) launched the Illumina/ACMG Foundation $200K Challenge for the fourth quarter of 2020. Longtime sponsor and Corporate Partner Program member Illumina pledged up to $200,000 to support the American College of Medical Genetics and Genomics’ (ACMG) new Evidence-Based Guidelines (EBG) Program.

With this latest sponsorship, Illumina is challenging companies and individuals to help fund ACMG’s recently created EBG Program. Illumina will match up to $200,000 in support in four giving categories: a $100K corporate match, two $45,000 corporate gifts, and one pool of $10,000 gifts that Illumina hopes will be matched by individual donors. To date, $220,000 of the possible $400,000 total has already been pledged.

“Having guidelines for genetic and genomic testing that are evidence driven and patient focused is critical to the appropriate adoption of personalized medicine. ACMG has demonstrated a strong commitment to building a robust, evidence-based guidelines program and their membership includes the expertise required,” said Phillip Febbo, MD, chief medical officer of Illumina. “We are thrilled to provide continued support through the Illumina matching challenge and hope to inspire a diverse network of community contributions while providing the financial support critical to sustaining the EBG Program.”

Just days after the matching challenge was announced, Invitae, another ACMG Foundation Corporate Partner, made a commitment of $100,000 to the Illumina/ACMG Foundation $200K Challenge, securing half of Illumina’s total pledge for the program.

Similarly, Evan and Cindy Jones of Teton Village, Wyoming, heard of the challenge and immediately provided a single matching contribution covering the individual donor portion of the $200K Challenge. Mr. Jones serves on the Board of Directors for the ACMG Foundation and is the Managing Member of jVen Capital, LLC. Jones said, “Cindy and I were excited to support the development of evidence-based guidelines. This work clearly helps improve patient care for those suffering from genetic disorders. It is even more exciting to know this contribution was doubled by Illumina.”

ACMG Foundation staff are working hard to identify donor companies who are willing to step up and support the last two $45,000 corporate gifts that will be matched by the Illumina sponsorship. Once found, this additional $180,000 will greatly strengthen the development of new evidence-based guidelines in 2021.

A third company, BioMarin Pharmaceuticals, did support the EBG Program with a $150,000 gift, but this donation occurred prior to Illumina’s pledge.

At present, the ACMG Foundation is on track to raise the $1 million needed annually to fully roll out this new EBG Program in 2021.

“The ACMG Foundation’s Guideline Development Fund will enable ACMG to hire a team of qualified methodologists and medical experts,” said ACMG’s CEO Max Muenke, MD, FACMG. “These highly skilled employees can then undertake the time-intensive work of systematic evidence review and guideline development, in partnership with volunteer teams of ACMG members and senior leaders. The ACMG Foundation’s role as the fundraising arm of ACMG ensures a firewall between the science

Read More
medicine

Worldwide Sports Medicine Device Industry to 2025 – Players Include Arthrex, Stryker & Zimmer Biomet Among Others – ResearchAndMarkets.com – Press Release

DUBLIN–(Business Wire)–The “Sports Medicine Device Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology, Product Type” report has been added to ResearchAndMarkets.com’s offering.

This report is a professional and in-depth study on the current state of the global Sports Medicine Device market with a focus on the Chinese market. The report provides key statistics on market of Sports Medicine Device. It is a valuable source of guidance and direction for companies and individuals interested in Sports Medicine Device industry.

Companies Covered:

  • Arthrex
  • Smith & Nephew
  • Stryker
  • Depuy Synthes/Johnson & Johnson
  • Zimmer Biomet
  • Karl Storz
  • Conmed
  • Wright
  • Medshape
  • Valeris
  • Rog
  • Aceosteo
  • Asco Medical
  • Atlas Surgical
  • Auxein
  • Biotek
  • Bonetech Medisys
  • CHM
  • Egifix
  • Forerunner
  • Fxorthopedi
  • Gesco Medical
  • GPC Medical Ltd
  • Green Surgical
  • Griphorto
  • Hardik International
  • HIBS
  • Innomed Solutions
  • Jeil Medical
  • Jiangsu Bai De Medical Instrument
  • Marapole
  • Matrix
  • Medgal
  • Microport
  • Miraclus
  • Narang
  • Naton Group
  • Nebula

Key points of Sports Medicine Device Market Report:

  1. The report provides a basic overview of Sports Medicine Device industry including: definition, applications and manufacturing technology.
  2. The report explores Global and Chinese major players in Sports Medicine Device market. In this part, the report presents the company profile, product specifications, capacity, production value, and 2015-2020 market shares for each company.
  3. The report depicts the global and Chinese total Sports Medicine Device market including: capacity, production, production value, cost/profit, supply/demand and Chinese import/export, by statistical analysis.
  4. The global Sports Medicine Device market is further divided by company, by country, and by application/type for the competitive landscape analysis.
  5. The report then estimates 2020-2025 development trends, analyse upstream raw materials, downstream demand, and current market dynamics of Sports Medicine Device market.
  6. The report makes some important proposals for a new project of Sports Medicine Device Industry before evaluating its feasibility.
  7. Overall, the report provides an in-depth insight of 2015-2025 global and Chinese Sports Medicine Device market covering all important parameters.

Key Topics Covered:

1.: Introduction of Sports Medicine Device Industry

1.1 Brief Introduction of Sports Medicine Device

1.2 Development of Sports Medicine Device Industry

1.3 Status of Sports Medicine Device Industry

2.: Manufacturing Technology of Sports Medicine Device

2.1 Development of Sports Medicine Device Manufacturing Technology

2.2 Analysis of Sports Medicine Device Manufacturing Technology

2.3 Trends of Sports Medicine Device Manufacturing Technology

3.: Analysis of Global Key Manufacturers

4.: 2015-2020 Global and Chinese Market of Sports Medicine Device

4.1 Market Size

4.1.1 2015-2020 Global Capacity, Production and Production Value of Sports Medicine Device Industry

4.1.2 2015-2020 Chinese Capacity, Production and Production Value of Sports Medicine Device Industry

4.2 2015-2020 Sports Medicine Device Industry Cost and Profit Estimation

4.3 Market Comparison of Global and Chinese Sports Medicine Device Industry

4.4 2015-2020 Global and Chinese Supply and Consumption of Sports Medicine Device

4.5 2015-2020 Import and Export of Sports Medicine Device

5.: Market Status of Sports Medicine Device Industry

5.1 Market Competition of Sports Medicine Device Industry by Company

5.2 Market Competition of Sports Medicine Device Industry by Region

5.3 Market Analysis of Sports Medicine Device Industry by

Read More
fitness

UAE’s Aster offers free fitness sessions, giveaways, discounted health check-ups

Dubai: Free fitness sessions, rewards, giveaways and discounted health check-ups on select days — a UAE-based health care group is going all out to promote fitness, health and wellbeing as the Dubai Fitness Challenge 2020 gets underway.

The move comes in the wake of the health care group – Aster Hospitals & Clinics UAE – becoming the official Hospitals and Clinics partner of the Dubai Fitness Challenge 2020.

The group, which has a network of four hospitals and 90 clinics in the country, said it is supporting the vision of Sheikh Hamdan Bin Mohammed bin Rashid Al Maktoum, Dubai Crown Prince and Chairman of The Executive Council of Dubai, to boost a healthy lifestyle through a simple task of performing 30 minutes of activity for 30 days straight, and thereby tackle the rising levels of obesity.

As official partner of DFC 2020, Aster said it will put all hands-on-deck to help residents do their part towards an active lifestyle. In order to achieve this objective, the group has launched a #LiveBetterwithAster campaign for residents of Dubai that will consist of free sessions with fitness experts and health checks at the Fitness Villages in Quranic Park and Kite Beach. In addition, residents can work on their own fitness and get rewarded for it through participation in contests and giveaways where they can win gift hampers and vouchers. Residents will also be able to avail special discounts in health check-ups, between October 30 and November 28, and avail them at any of the Aster hospitals and clinics in UAE before December 31, 2020.

Dr Sherbaz Bichu, CEO of Aster Hospitals & Clinics UAE, said, “As leading healthcare providers in the region, the objectives of the Dubai Fitness Challenge work in symbiosis with our long-term goals to improve quality of life of the residents of the country. As official partners, Aster Hospitals & Clinics will be working on various initiatives to help motivate residents of Dubai to inculcate fitness regimes as part of their daily lifestyle. We have also launched several initiatives to motivate our own employees to participate in this campaign.”

Aster has also launched the Aster Wellbeing Programme, a group-wide campaign to drive employee wellbeing through individual and group initiatives during the month of November. Various fitness sessions are being conducted in various Aster hospital and clinic units for their employees, as well as employees based in Aster units across seven countries. Fitness challenges and activities have also been introduced for employees to participate in and support their own overall wellbeing.

Source Article

Read More